Payment overview · 2025
General Payments
$109.17
5 reported records · 3 companies
Healthcare provider profile · identity verified
Justin Olswanger, DO
Allopathic & Osteopathic Physicians|Family Medicine · WALLA WALLA, WA · NPI 1033265657
Verified facts
What the public records show
CMS Open Payments records show Justin Olswanger, DO received $109.17 in general payments during 2025 across 5 reported records.
PFIZER INC. accounted for 47.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.98 | 47.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.54 | 35.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.65 | 17.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $70.63 | 4 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.98 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $51.98 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $38.54 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 396 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 330 | 93 |
| Losartan Potassium | Losartan Potassium | 292 | 75 |
| Omeprazole | Omeprazole | 237 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 229 | 47 |
| Gabapentin | Gabapentin | 225 | 49 |
| Tramadol Hcl | Tramadol Hcl | 222 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 182 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 180 | 58 |
| Metformin Hcl | Metformin Hcl | 176 | 54 |
| Pregabalin | Pregabalin | 162 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 155 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 39 |
| Potassium Chloride | Potassium Chloride | 148 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 40 |
| Lisinopril | Lisinopril | 131 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 130 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 36 |
| Trazodone Hcl | Trazodone Hcl | 123 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 24 |
| Furosemide | Furosemide | 117 | 28 |
| Bupropion Hcl Sr | Bupropion Hcl | 115 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 33 |
| Sertraline Hcl | Sertraline Hcl | 107 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 95 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 22 |
| Buspirone Hcl | Buspirone Hcl | 86 | 14 |
| Alprazolam | Alprazolam | 83 | 16 |
| Lorazepam | Lorazepam | 81 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 75 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 73 | 14 |
| Ondansetron Odt | Ondansetron | 71 | 22 |
| Prednisone | Prednisone | 71 | 33 |
| Clonazepam | Clonazepam | 68 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 19 |
| Estradiol | Estradiol | 63 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | suppressed |
| Meloxicam | Meloxicam | 59 | 17 |
| Donepezil Hcl | Donepezil Hcl | 58 | 14 |
| Metformin Hcl Er | Metformin Hcl | 57 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 13 |
| Famotidine | Famotidine | 54 | 14 |
| Allopurinol | Allopurinol | 53 | 12 |
| Atenolol | Atenolol | 53 | 17 |
| Methocarbamol | Methocarbamol | 52 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 14 |
| Risperidone | Risperidone | 50 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 47 | suppressed |
| Spironolactone | Spironolactone | 47 | 12 |
| Alendronate Sodium | Alendronate Sodium | 46 | 12 |
| Eszopiclone | Eszopiclone | 46 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 46 | 12 |
| Eliquis | Apixaban | 44 | suppressed |
| Ibuprofen | Ibuprofen | 44 | suppressed |
| Mupirocin | Mupirocin | 44 | 19 |
| Rizatriptan | Rizatriptan Benzoate | 44 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 14 |
| Topiramate | Topiramate | 39 | suppressed |
| Lactulose | Lactulose | 37 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 13 |
| Simvastatin | Simvastatin | 35 | 11 |
| Lovastatin | Lovastatin | 34 | 11 |
| Naproxen | Naproxen | 34 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 24 |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 18 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Nystatin | Nystatin | 26 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Nadolol | Nadolol | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Diazepam | Diazepam | 17 | 12 |
| Fluconazole | Fluconazole | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Indomethacin | Indomethacin | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Savella | Milnacipran Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Glatopa | Glatiramer Acetate | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $109.17 · 5 records | PFIZER INC. | NURTEC ODT, QULIPTA, REXULTI, UBRELVY, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error